Table 2.
Venous thromboembolism (VTE) events and nonadministration of pharmacologic VTE prophylaxis on both patient and dose levels comparing patients by COVID-19 testing Status (positive vs. negative vs. not-tested)
| Tested (+) for COVID-19 | Tested (−) for COVID-19 | Not tested for COVID-19 | P† | aOR (95% CI) Tested (+) for COVID-19 versus Others | |
|---|---|---|---|---|---|
| Patient visit level | |||||
| Total number of patient visits | 439 | 2316 | 3035 | ||
| Prescribed pharmacologic VTE prophylaxis, n (%) | 383/439 (87.2) | 1177/2136 (53.2) | 1435/3035 (49.3) | < 0.001 | 1.51 (1.38, 1.66)§ |
| Received all doses, n (%) | 281/383 (73.4) | 724/1177 (61.5) | 917/1435 (63.9) | < 0.001 | 1.48 (1.36, 1.62)* |
| Number of Patients who Developed VTE During Hospitalization, n (%) | 11/439 (2.5) | 6/2136 (0.3) | 15/3035 (0.5) | < 0.001 | 1.08 (0.48, 2.44)§ |
| DVT only | 4/439(0.9) | 1/2136 (0.04) | 8/3035 (0.3) | 0.005 | 0.92 (0.41, 2.07)§ |
| PE only | 6/439(1.4) | 5/2136 (0.2) | 6/3035 (0.2) | 0.002 | 1.93 (0.94, 3.95)§ |
| Both DVT and PE | 1/439 (0.2) | 0/2136 (0.0) | 1/3035 (0.03) | 0.15 | 1.75 (0.25, 12.22)§ |
| Patients with VTE who were prescribed VTE prophylaxis, n (%) | 11/11 (100) | 6/6 (100) | 15/15 (100) | 1.00 | |
| Patients with VTE who missed any dose of VTE prophylaxis, n (%) | 4/11 (36.4) | 3/6 (50.0) | 10/15 (66.7) | 0.31 | |
| Dose level | |||||
| Number of doses prescribed | 5518 | 12,814 | 18,770 | ||
| Missed doses, n (%) | 215/5518 (3.9) | 1121/12,814 (8.7) | 1494/18,770 (8.0) | < 0.001 | 0.82 (0.77, 0.87)* |
| Refused doses, n (%) | 108/5518 (2.0) | 735/12,814 (5.7) | 982/18,770 (5.2) | < 0.001 | 0.76 (0.71, 0.82)* |
| Other reasons for missed doses, n (%) | 107/5,518 (1.9) | 386/12,814 (3.0) | 512/18,770 (2.7) | < 0.001 | 0.95 (0.86, 1.05)* |
aOR adjusted odds ratio, CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, VTE venous thromboembolism
†P values calculated using the Chi-square test and Fisher's exact test
§aOR calculated after adjusting for variables found to be statistically significantly different between the groups in Table 1 (age, race, ethnicity, hospital length of stay, body mass index, ventilation, and death)
*Separate univariate analysis, including only patients who were prescribed prophylaxis, showed a significant difference in race, ethnicity, hospital length of stay, body mass index, ventilation, and death between the three groups. Thus, in multiple logistic regression, we adjusted for these variables